|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fujitani K: Overview of adjuvant and
neoadjuvant therapy for resectable gastric cancer in the East. Dig
Surg. 30:119–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant
capecitabine and oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled
trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakajima T, Kinoshita T, Nashimoto A,
Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M
and Ohashi Y: National Surgical Adjuvant Study of Gastric Cancer
Group: Randomized controlled trial of adjuvant uracil-tegafur
versus surgery alone for serosa-negative, locally advanced gastric
cancer. Br J Surg. 94:1468–1476. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Banys-Paluchowski M, Schütz F, Ruckhäberle
E, Krawczyk N and Fehm T: Metronomic chemotherapy for metastatic
breast cancer - a systematic review of the literature. Geburtshilfe
Frauenheilkd. 76:525–534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pasquier E, Kavallaris M and André N:
Metronomic chemotherapy: New rationale for new directions. Nat Rev
Clin Oncol. 7:455–465. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi H, Jiang J, Ji J, Shi M, Cai Q, Chen
X, Yu Y, Liu B, Zhu Z and Zhang J: Anti-angiogenesis participates
in antitumor effects of metronomic capecitabine on colon cancer.
Cancer Lett. 349:128–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan F, Shi H, Ji J, Cai Q, Chen X, Yu Y,
Liu B, Zhu Z and Zhang J: Capecitabine metronomic chemotherapy
inhibits the proliferation of gastric cancer cells through
anti-angiogenesis. Oncol Rep. 33:1753–1762. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Browder T, Butterfield CE, Kräling BM, Shi
B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling
of chemotherapy improves efficacy against experimental
drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
|
|
11
|
Wang W, McLeod HL, Cassidy J and
Collie-Duguid ES: Mechanisms of acquired chemoresistance to
5-fluorouracil and tomudex: Thymidylate synthase dependent and
independent networks. Cancer Chemother Pharmacol. 59:839–845. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Guan J, Long X, Wang Y and Xiang X:
mir-1-mediated paracrine effect of cancer-associated fibroblasts on
lung cancer cell proliferation and chemoresistance. Oncol Rep.
35:3523–3531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shintani Y, Fujiwara A, Kimura T, Kawamura
T, Funaki S, Minami M and Okumura M: IL-6 secreted from cancer
associated fibroblasts mediates chemoresistance in NSCLC by
increasing epithelial-mesenchymal transition signaling. J Thorac
Oncol. 11:1482–1492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lotti F, Jarrar AM, Pai RK, Hitomi M,
Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A,
et al: Chemotherapy activates cancer-associated fibroblasts to
maintain colorectal cancer-initiating cells by IL-17A. J Exp Med.
210:2851–2872. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka K, Miyata H, Sugimura K, Fukuda S,
Kanemura T, Yamashita K, Miyazaki Y, Takahashi T, Kurokawa Y,
Yamasaki M, et al: miR-27 is associated with chemoresistance in
esophageal cancer through transformation of normal fibroblasts to
cancer-associated fibroblasts. Carcinogenesis. 36:894–903. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amornsupak K, Insawang T, Thuwajit P,
O-Charoenrat P, Eccles SA and Thuwajit C: Cancer-associated
fibroblasts induce high mobility group box 1 and contribute to
resistance to doxorubicin in breast cancer cells. BMC Cancer.
14:9552014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao W, Chen R, Zhao M, Li L, Fan L and
Che XM: High glucose promotes gastric cancer chemoresistance in
vivo and in vitro. Mol Med Rep. 12:843–850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Geng M, Wang L, Chen X, Cao R and Li P:
The association between chemosensitivity and Pgp, GST-π and Topo II
expression in gastric cancer. Diagn Pathol. 8:1982013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Verset L, Tommelein J, Lopez Moles X,
Decaestecker C, Boterberg T, De Vlieghere E, Salmon I, Mareel M,
Bracke M, De Wever O and Demetter P: Impact of neoadjuvant therapy
on cancer-associated fibroblasts in rectal cancer. Radiother Oncol.
116:449–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan H, Guo BY and Zhang S:
Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis
in ovarian cancer cells by promoting STAT3 signaling. Biochem
Biophys Res Commun. 470:947–954. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steinbichler TB, Metzler V, Pritz C,
Riechelmann H and Dudas J: Tumor-associated fibroblast-conditioned
medium induces CDDP resistance in HNSCC cells. Oncotarget.
7:2508–2518. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hara M, Nagasaki T, Shiga K and Takeyama
H: Suppression of cancer-associated fibroblasts and endothelial
cells by itraconazole in bevacizumab-resistant gastrointestinal
cancer. Anticancer Res. 36:169–177. 2016.PubMed/NCBI
|
|
25
|
Salnikov AV, Heldin NE, Stuhr LB, Wiig H,
Gerber H, Reed RK and Rubin K: Inhibition of carcinoma cell-derived
VEGF reduces inflammatory characteristics in xenograft carcinoma.
Int J Cancer. 119:2795–2802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J and Liu J: Tumor stroma as targets
for cancer therapy. Pharmacol Ther. 137:200–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Franco OE, Shaw AK, Strand DW and Hayward
SW: Cancer associated fibroblasts in cancer pathogenesis. Semin
Cell Dev Biol. 21:33–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan Y, Wang LF and Wang RF: Role of
cancer-associated fibroblasts in invasion and metastasis of gastric
cancer. World J Gastroenterol. 21:9717–9726. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rudin CM, Brahmer JR, Juergens RA, Hann
CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P and Liu JO:
Phase 2 study of pemetrexed and itraconazole as second-line therapy
for metastatic nonsquamous non-small-cell lung cancer. J Thorac
Oncol. 8:619–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
